Pyrido-pyridazine derivatives as ligands for GABA receptors
    12.
    发明授权
    Pyrido-pyridazine derivatives as ligands for GABA receptors 失效
    吡啶并哒嗪衍生物作为GABA受体的配体

    公开(公告)号:US06593325B1

    公开(公告)日:2003-07-15

    申请号:US10069379

    申请日:2002-02-20

    IPC分类号: A61K315025

    CPC分类号: C07D471/04

    摘要: A class of pyrido[2,3-d]pyridazine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 8-position, a substituted alkoxy moiety at the 2-position, and a range of substituents at the 3-position, are selective ligands for GABAA receptors, in particular having high affinity for the &agr;2 and/or &agr;3 and/or &agr;5 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.

    摘要翻译: 一类吡啶并[2,3-d]哒嗪衍生物,其在8-位上具有任选取代的环烷基,苯基或杂芳基取代基,2-位上的取代烷氧基部分和3-位上的取代基范围 是用于GABA A受体的选择性配体,特别是对α2和/或α3和/或α5亚基具有高亲和力,因此有益于治疗和/或预防中枢神经系统的不良状况,包括焦虑 抽搐和认知障碍。

    Triazolo-pyridazine derivatives as ligands for GABA receptors
    14.
    发明授权
    Triazolo-pyridazine derivatives as ligands for GABA receptors 失效
    三唑并哒嗪衍生物作为GABA受体的配体

    公开(公告)号:US06303597B1

    公开(公告)日:2001-10-16

    申请号:US09582444

    申请日:2000-06-26

    IPC分类号: A61K315025

    CPC分类号: C07D487/04

    摘要: 1,2,4-triazolo[4,3-b]pyridazine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 3-position, a substituted alkoxy moiety at the 6-position, and an optionally substituted bicycloalkyl ring system at the 7-position, are selective ligands for GABAA receptors, in particular having high affinity for the &agr;2 and/or &agr;3 subunit thereof, are useful in the treatment of anxiety and convulsions.

    摘要翻译: 在3位具有任选取代的环烷基,苯基或杂芳基取代基,6位取代的烷氧基部分和任选取代的双环烷基环系统的1,2,4-三唑并[4,3-b]哒嗪衍生物 在7位是GABA A受体的选择性配体,特别是对其α2和/或α3亚基具有高亲和力,可用于治疗焦虑和抽搐。

    Azetidine, pyrrolidine and piperidine derivatives as 5-HT receptor
agonists
    16.
    发明授权
    Azetidine, pyrrolidine and piperidine derivatives as 5-HT receptor agonists 失效
    氮杂环丁烷,吡咯烷和哌啶衍生物作为5-HT受体激动剂

    公开(公告)号:US6140347A

    公开(公告)日:2000-10-31

    申请号:US171208

    申请日:1998-10-14

    摘要: A class of compounds of formula (I) wherein Z, E, Q, T, U, V, W, M, R.sup.1, R.sup.7 and R.sup.8 are as defined herein; are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists. ##STR1##

    摘要翻译: PCT No.PCT / GB97 / 01137 Sec。 371日期:1998年10月14日 102(e)日期1998年10月14日PCT 1997年4月24日PCT公布。 出版物WO97 / 42189 日期:1997年11月13日一类其中Z,E,Q,T,U,V,W,M,R 1,R 7和R 8如本文所定义的式(I)化合物; 是5-HT1样受体的选择性激动剂,其是人类5-HT1Dα受体亚型的有效激动剂,同时相对于5-HT1Dβ亚型对5-HT1Dα受体亚型具有至少10倍的选择性亲和力; 因此,它们可用于治疗和/或预防临床状况,特别是偏头痛和相关疾病,其中指出5-HT1D受体的亚型选择性激动剂,同时引起较少的副作用,特别是不利的心血管事件,比 与非亚型选择性5-HT1D受体激动剂相关的那些。

    Azetidine, pyrrolidine and piperidine derivatives as 5-HT.sub.1D
receptor agonists
    17.
    发明授权
    Azetidine, pyrrolidine and piperidine derivatives as 5-HT.sub.1D receptor agonists 失效
    氮杂环丁烷,吡咯烷和哌啶衍生物作为5-HT1D受体激动剂

    公开(公告)号:US6127388A

    公开(公告)日:2000-10-03

    申请号:US171929

    申请日:1998-10-26

    CPC分类号: C07D405/14

    摘要: A class of substituted azetidine, pyrrolidine and piperidine derivatives of Formula I are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists. ##STR1##

    摘要翻译: PCT No.PCT / GB97 / 01330 Sec。 371日期:1998年10月26日 102(e)日期1998年10月26日PCT提交1997年5月15日PCT公布。 公开号WO97 / 45426 PCT 日期1997年12月4日一类式I的取代的氮杂环丁烷,吡咯烷和哌啶衍生物是5-HT1样受体的选择性激动剂,是人类5-HT1Dα受体亚型的有效激动剂,同时具有至少10倍的选择性 相对于5-HT1Dβ亚型的5-HT1Dα受体亚型的亲和力; 因此,它们可用于治疗和/或预防临床状况,特别是偏头痛和相关疾病,其中指出5-HT1D受体的亚型选择性激动剂,同时引起较少的副作用,特别是不利的心血管事件,比 与非亚型选择性5-HT1D受体激动剂相关的那些。

    Triazole derivatives
    19.
    发明授权
    Triazole derivatives 失效
    三唑衍生物

    公开(公告)号:US5902819A

    公开(公告)日:1999-05-11

    申请号:US676350

    申请日:1996-07-19

    摘要: Triazole derivatives represented by formula (IIA), and salts and prodrug thereof, wherein R.sup.1 represents C.sub.1-6 alkoxy(C.sub.1-6)alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl(C.sub.1-6)alkyl, aryl, aryl(C.sub.1-6)alkyl, aryloxy(C.sub.1-6)alkyl, aryl(C.sub.2-6)alkenyl, aryl(C.sub.2-6)alkynyl, C.sub.3-7 heterocycloalkyl(C.sub.1-6)alkyl, heteroaryl, heteroaryl(C.sub.1-6)alkyl, heteroaryl(C2-6)alkenyl or heteroaryl(C.sub.2-6)alkynyl, any of which groups may be optionally substituted; are selective agonist of 5-HT.sub.1 -like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated. ##STR1##

    摘要翻译: PCT No.PCT / GB95 / 00134 Sec。 371日期:1996年7月19日 102(e)日期1996年7月19日PCT提交1995年1月24日PCT公布。 WO95 / 21166 PCT公开 日期:1995年8月10日由式(IIA)表示的三唑衍生物及其盐和前药,其中R1表示C1-6烷氧基(C1-6)烷基,C2-6烯基,C2-6炔基,C3-7环烷基,C3 (C 1-6)烷基,芳基(C 1-6)烷基,芳氧基(C 1-6)烷基,芳基(C 2-6)烯基,芳基(C 2-6)炔基,C 3-7杂环烷基 -6)烷基,杂芳基,杂芳基(C 1-6)烷基,杂芳基(C + Z 2-6)烯基或杂芳基(C 2-6)炔基,其中任何基团可任选被取代; 是5-HT1样受体的选择性激动剂,因此可用于治疗临床病症,特别是偏头痛和相关疾病,其中指出了这些受体的选择性激动剂。